Diabetes Mellitus and Dementia

  • Toshiharu NinomiyaEmail author
Diabetes and Other Diseases-Emerging Associations (JJ Nolan, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Diabetes and Other Diseases-Emerging Associations


Growing epidemiologic evidence has suggested that people with diabetes mellitus are at an increased risk for the development of dementia. However, the results for the subtypes of dementia are inconsistent. This review examines the risk of dementia in people with diabetes mellitus, and discusses the possible mechanism underpinning this association. Diabetes mellitus is associated with a 1.5- to 2.5-fold greater risk of dementia among community-dwelling elderly people. Notably, diabetes mellitus is a significant risk factor for not only vascular dementia, but also Alzheimer’s disease. The mechanisms underpinning the association are unclear, but it may be multifactorial in nature, involving factors such as cardiovascular risk factors, glucose toxicity, changes in insulin metabolism and inflammation. The optimal management of these risk factors in early life may be important to prevent late-life dementia. Furthermore, novel therapeutic strategies will be needed to prevent or reduce the development of dementia in people with diabetes mellitus.


Diabetes mellitus Dementia Alzheimer’s disease Vascular dementia Epidemiology Prospective study 


Compliance with Ethics Guidelines

Conflict of Interest

Toshiharu Ninomiya declares that he has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    World Health Organization and Alzheimer’s Disease International. Dementia. A public health priority. Available at: Accessed 18 Aug 2013.
  2. 2.
    World health organization. World health report 2003-shaping the future. Geneva: WHO. 2003.Google Scholar
  3. 3.
    The IDF Diabetes Atlas, 5th edition. Available at: http://www.Idf.Org/diabetesatlas/5e/diabetes. Accessed 26 Jul 2013.
  4. 4.•
    Lu FP, Lin KP, Kuo HK. Diabetes and the risk of multi-system aging phenotypes: a systematic review and meta-analysis. PloS One. 2009;4:e4144. This study provides the comprehensive information about the influence of diabetes mellitus on the risk of geriatric health complications.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol. 2006;5:64–74.PubMedCrossRefGoogle Scholar
  6. 6.
    Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol. 2009;66:200–8.PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Matsui Y, Tanizaki Y, Arima H, Yonemoto K, Doi Y, Ninomiya T, et al. Incidence and survival of dementia in a general population of Japanese elderly: the Hisayama Study. J Neurol Neurosurg Psychiatry. 2009;80:366–70.PubMedCrossRefGoogle Scholar
  8. 8.
    Leibson CL, Rocca WA, Hanson VA, Cha R, Kokmen E, O'Brien PC, et al. Risk of dementia among persons with diabetes mellitus: a population-based cohort study. Am J Epidemiol. 1997;145:301–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurology. 1999;53:1937–42.PubMedCrossRefGoogle Scholar
  10. 10.
    Luchsinger JA, Tang MX, Stern Y, Shea S, Mayeux R. Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol. 2001;154:635–41.PubMedCrossRefGoogle Scholar
  11. 11.
    MacKnight C, Rockwood K, Awalt E, McDowell I. Diabetes mellitus and the risk of dementia, Alzheimer's disease and vascular cognitive impairment in the Canadian Study of Health and Aging. Dement Geriatr Cogn Disord. 2002;14:77–83.PubMedCrossRefGoogle Scholar
  12. 12.
    Peila R, Rodriguez BL, Launer LJ. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia Aging Study. Diabetes. 2002;51:1256–62.PubMedCrossRefGoogle Scholar
  13. 13.
    Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol. 2004;61:661–6.PubMedCrossRefGoogle Scholar
  14. 14.
    Akomolafe A, Beiser A, Meigs JB, Au R, Green RC, Farrer LA, et al. Diabetes mellitus and risk of developing Alzheimer disease: results from the Framingham Study. Arch Neurol. 2006;63:1551–5.PubMedCrossRefGoogle Scholar
  15. 15.
    Irie F, Fitzpatrick AL, Lopez OL, Kuller LH, Peila R, Newman AB, et al. Enhanced risk for Alzheimer disease in persons with type 2 diabetes and ApoE epsilon4: the Cardiovascular Health Study Cognition Study. Arch Neurol. 2008;65:89–93.PubMedCrossRefGoogle Scholar
  16. 16.
    Raffaitin C, Gin H, Empana JP, Helmer C, Berr C, Tzourio C, et al. Metabolic syndrome and risk for incident Alzheimer's disease or vascular dementia: the Three-city Study. Diabetes Care. 2009;32:169–74.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Alonso A, Mosley Jr TH, Gottesman RF, Catellier D, Sharrett AR, Coresh J. Risk of dementia hospitalisation associated with cardiovascular risk factors in midlife and older age: the Atherosclerosis Risk In Communities (ARIC) Study. J Neurol Neurosurg Psychiatry. 2009;80:1194–201.PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Ronnemaa E, Zethelius B, Sundelof J, Sundstrom J, Degerman-Gunnarsson M, Lannfelt L, et al. Glucose metabolism and the risk of Alzheimer's disease and dementia: a population-based 12-year follow-up study in 71-year-old men. Diabetologia. 2009;52:1504–10.PubMedCrossRefGoogle Scholar
  19. 19.
    Xu WL, von Strauss E, Qiu CX, Winblad B, Fratiglioni L. Uncontrolled diabetes increases the risk of Alzheimer's disease: a population-based cohort study. Diabetologia. 2009;52:1031–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Ahtiluoto S, Polvikoski T, Peltonen M, Solomon A, Tuomilehto J, Winblad B, et al. Diabetes, Alzheimer disease, and vascular dementia: a population-based neuropathologic study. Neurology. 2010;75:1195–202.PubMedCrossRefGoogle Scholar
  21. 21.
    Mejia-Arango S. Zuniga-Gil C [diabetes mellitus as a risk factor for dementia in the Mexican elder population]. Rev Neurol. 2011;53:397–405.PubMedGoogle Scholar
  22. 22.•
    Ohara T, Doi Y, Ninomiya T, Hirakawa Y, Hata J, Iwaki T, et al. Glucose tolerance status and risk of dementia in the community: the Hisayama Study. Neurology. 2011;77:1126–34. This study provides the reliable findings of the relationship between diabetes-related factors and dementia, because the diabetes status and outcomes were ascertained precisely.PubMedCrossRefGoogle Scholar
  23. 23.
    Cheng D, Noble J, Tang MX, Schupf N, Mayeux R, Luchsinger JA. Type 2 diabetes and late-onset Alzheimer's disease. Dement Geriatr Cogn Disord. 2011;31:424–30.PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Hassing LB, Johansson B, Nilsson SE, Berg S, Pedersen NL, Gatz M, et al. Diabetes mellitus is a risk factor for vascular dementia, but not for Alzheimer's disease: a population-based study of the oldest old. Int Psychogeriatr. 2002;14:239–48.PubMedCrossRefGoogle Scholar
  25. 25.
    Hayden KM, Zandi PP, Lyketsos CG, Khachaturian AS, Bastian LA, Charoonruk G, et al. Vascular risk factors for incident Alzheimer disease and vascular dementia: the Cache county Study. Alzheimer Dis Assoc Disord. 2006;20:93–100.PubMedCrossRefGoogle Scholar
  26. 26.
    Thacker EL, Psaty BM, McKnight B, Heckbert SR, Longstreth Jr WT, Mukamal KJ, et al. Fasting and post-glucose load measures of insulin resistance and risk of ischemic stroke in older adults. Stroke. 2011;42:3347–51.PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Doi Y, Ninomiya T, Hata J, Fukuhara M, Yonemoto K, Iwase M, et al. Impact of glucose tolerance status on development of ischemic stroke and coronary heart disease in a general Japanese population: the Hisayama Study. Stroke. 2010;41:203–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol. 1991;82:239–59.PubMedCrossRefGoogle Scholar
  29. 29.
    Gosche KM, Mortimer JA, Smith CD, Markesbery WR, Snowdon DA. Hippocampal volume as an index of Alzheimer neuropathology: findings from the Nun Study. Neurology. 2002;58:1476–82.PubMedCrossRefGoogle Scholar
  30. 30.
    Convit A, De Leon MJ, Tarshish C, De Santi S, Tsui W, Rusinek H, et al. Specific hippocampal volume reductions in individuals at risk for Alzheimer's disease. Neurobiol Aging. 1997;18:131–8.PubMedCrossRefGoogle Scholar
  31. 31.
    Schott JM, Fox NC, Frost C, Scahill RI, Janssen JC, Chan D, et al. Assessing the onset of structural change in familial Alzheimer's disease. Ann Neurol. 2003;53:181–8.PubMedCrossRefGoogle Scholar
  32. 32.
    Krasuski JS, Alexander GE, Horwitz B, Daly EM, Murphy DG, Rapoport SI, et al. Volumes of medial temporal lobe structures in patients with Alzheimer's disease and mild cognitive impairment (and in healthy controls). Biol Psychiatry. 1998;43:60–8.PubMedCrossRefGoogle Scholar
  33. 33.
    den Heijer T, Vermeer SE, van Dijk EJ, Prins ND, Koudstaal PJ, Hofman A, et al. Type 2 diabetes and atrophy of medial temporal lobe structures on brain MRI. Diabetologia. 2003;46:1604–10.CrossRefGoogle Scholar
  34. 34.
    Matsuzaki T, Sasaki K, Tanizaki Y, Hata J, Fujimi K, Matsui Y, et al. Insulin resistance is associated with the pathology of Alzheimer disease: the Hisayama Study. Neurology. 2010;75:764–70.PubMedCrossRefGoogle Scholar
  35. 35.
    Pfeifer LA, White LR, Ross GW, Petrovitch H, Launer LJ. Cerebral amyloid angiopathy and cognitive function: the HAAS Autopsy Study. Neurology. 2002;58:1629–34.PubMedCrossRefGoogle Scholar
  36. 36.
    Mankovsky BN, Ziegler D. Stroke in patients with diabetes mellitus. Diabetes Metab Res Rev. 2004;20:268–87.PubMedCrossRefGoogle Scholar
  37. 37.
    Kalmijn S, Foley D, White L, Burchfiel CM, Curb JD, Petrovitch H, et al. Metabolic cardiovascular syndrome and risk of dementia in Japanese-American elderly men. the Honolulu-Asia Aging Study. Arterioscler Thromb Vasc Biol. 2000;20:2255–60.PubMedCrossRefGoogle Scholar
  38. 38.
    Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology. 2005;64:277–81.PubMedCrossRefGoogle Scholar
  39. 39.
    Serlin Y, Levy J, Shalev H. Vascular pathology and blood-brain barrier disruption in cognitive and psychiatric complications of type 2 diabetes mellitus. Cardiovasc Psychiatry Neurol. 2011;2011:609202.PubMedCentralPubMedCrossRefGoogle Scholar
  40. 40.
    McGuinness B, Todd S, Passmore P, Bullock R. Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database Syst Rev. 2009:CD004034.Google Scholar
  41. 41.
    Tzourio C, Anderson C, Chapman N, Woodward M, Neal B, MacMahon S, et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med. 2003;163:1069–75.PubMedCrossRefGoogle Scholar
  42. 42.
    McGuinness B, Craig D, Bullock R, Passmore P. Statins for the prevention of dementia. Cochrane Database Syst Rev. 2009;2, CD003160.PubMedGoogle Scholar
  43. 43.
    Qiu C, Winblad B, Fratiglioni L. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol. 2005;4:487–99.PubMedCrossRefGoogle Scholar
  44. 44.
    Ninomiya T, Ohara T, Hirakawa Y, Yoshida D, Doi Y, Hata J, et al. Midlife and late-life blood pressure and dementia in Japanese elderly: the Hisayama Study. Hypertension. 2011;58:22–8.PubMedCrossRefGoogle Scholar
  45. 45.
    Sommerfield AJ, Deary IJ, Frier BM. Acute hyperglycemia alters mood state and impairs cognitive performance in people with type 2 diabetes. Diabetes Care. 2004;27:2335–40.PubMedCrossRefGoogle Scholar
  46. 46.
    Jacobson AM, Musen G, Ryan CM, Silvers N, Cleary P, Waberski B, et al. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group. Long-term effect of diabetes and its treatment on cognitive function. N Engl J Med. 2007;356:1842–52.PubMedCrossRefGoogle Scholar
  47. 47.
    Biessels GJ, Kamal A, Ramakers GM, Urban IJ, Spruijt BM, Erkelens DW, et al. Place learning and hippocampal synaptic plasticity in streptozotocin-induced diabetic rats. Diabetes. 1996;45:1259–66.PubMedCrossRefGoogle Scholar
  48. 48.
    Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813–20.PubMedCrossRefGoogle Scholar
  49. 49.•
    Launer LJ, Miller ME, Williamson JD, Lazar RM, Gerstein HC, Murray AM, et al. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (accord mind): a randomized open-label substudy. Lancet Neurol. 2011;10:969–77. This study is a randomized control trial addressing the treatment effect of the tight glucose control on the cognitive function and the morphologic changes of the brain.PubMedCentralPubMedCrossRefGoogle Scholar
  50. 50.
    Whitmer RA, Karter AJ, Yaffe K, Quesenberry Jr CP, Selby JV. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA. 2009;301:1565–72.PubMedCentralPubMedCrossRefGoogle Scholar
  51. 51.
    Lin CH, Sheu WH. Hypoglycaemic episodes and risk of dementia in diabetes mellitus: 7-year follow-up study. J Intern Med. 2013;273:102–10.PubMedCrossRefGoogle Scholar
  52. 52.
    de Galan BE, Zoungas S, Chalmers J, Anderson C, Dufouil C, Pillai A, et al. ADVANCE Collaborative Group. Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. Diabetologia. 2009;52:2328–36.PubMedCrossRefGoogle Scholar
  53. 53.
    Fanelli CG, Porcellati F, Pampanelli S, Bolli GB. Insulin therapy and hypoglycaemia: the size of the problem. Diabetes Metab Res Rev. 2004;20 Suppl 2:S32–42.PubMedCrossRefGoogle Scholar
  54. 54.
    Wright RJ, Frier BM. Vascular disease and diabetes: is hypoglycaemia an aggravating factor? Diabetes Metab Res Rev. 2008;24:353–63.PubMedCrossRefGoogle Scholar
  55. 55.
    Artola A, Kamal A, Ramakers GM, Gardoni F, Di Luca M, Biessels GJ, et al. Synaptic plasticity in the diabetic brain: advanced aging? Prog Brain Res. 2002;138:305–14.PubMedCrossRefGoogle Scholar
  56. 56.
    Gispen WH, Biessels GJ. Cognition and synaptic plasticity in diabetes mellitus. Trends Neurosci. 2000;23:542–9.PubMedCrossRefGoogle Scholar
  57. 57.
    Zhao WQ, Alkon DL. Role of insulin and insulin receptor in learning and memory. Mol Cell Endocrinol. 2001;177:125–34.PubMedCrossRefGoogle Scholar
  58. 58.
    Zemva J, Schubert M. Central insulin and insulin-like growth factor-1 signaling: implications for diabetes associated dementia. Curr Diabetes Rev. 2011;7:356–66.PubMedCrossRefGoogle Scholar
  59. 59.
    Salkovic-Petrisic M, Osmanovic J, Grünblatt E, Riederer P, Hoyer S. Modeling sporadic Alzheimer's disease: the insulin resistant brain state generates multiple long-term morphobiological abnormalities including hyperphosphorylated tau protein and amyloid-beta. J Alzheimers Dis. 2009;18:729–50.PubMedGoogle Scholar
  60. 60.
    Neumann KF, Rojo L, Navarrete LP, Farias G, Reyes P, Maccioni RB. Insulin resistance and Alzheimer's disease: molecular links & clinical implications. Curr Alzheimer Res. 2008;5:438–47.PubMedCrossRefGoogle Scholar
  61. 61.
    Craft S, Peskind E, Schwartz MW, Schellenberg GD, Raskind M, Porte Jr D. Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein e genotype. Neurology. 1998;50:164–8.PubMedCrossRefGoogle Scholar
  62. 62.
    Craft S, Watson GS. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol. 2004;3:169–78.PubMedCrossRefGoogle Scholar
  63. 63.
    Nesto R. C-reactive protein, its role in inflammation, type 2 diabetes and cardiovascular disease, and the effects of insulin-sensitizing treatment with thiazolidinediones. Diabet Med. 2004;21:810–7.PubMedCrossRefGoogle Scholar
  64. 64.
    Doi Y, Kiyohara Y, Kubo M, Ninomiya T, Wakugawa Y, Yonemoto K, et al. Elevated c-reactive protein is a predictor of the development of diabetes in a general Japanese population: the Hisayama Study. Diabetes Care. 2005;28:2497–500.PubMedCrossRefGoogle Scholar
  65. 65.
    Schmidt MI, Duncan BB, Sharrett AR, Lindberg G, Savage PJ, Offenbacher S, et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk In Communities Study): a cohort study. Lancet. 1999;353:1649–52.PubMedCrossRefGoogle Scholar
  66. 66.
    Lee CC, Adler AI, Sandhu MS, Sharp SJ, Forouhi NG, Erqou S, et al. Association of c-reactive protein with type 2 diabetes: prospective analysis and meta-analysis. Diabetologia. 2009;52:1040–7.PubMedCrossRefGoogle Scholar
  67. 67.
    Schram MT, Euser SM, de Craen AJ, Witteman JC, Frolich M, Hofman A, et al. Systemic markers of inflammation and cognitive decline in old age. J Am Geriatr Soc. 2007;55:708–16.PubMedCrossRefGoogle Scholar
  68. 68.
    Alley DE, Crimmins EM, Karlamangla A, Hu P, Seeman TE. Inflammation and rate of cognitive change in high-functioning older adults. J Gerontol A Biol Sci Med Sci. 2008;63:50–5.PubMedCentralPubMedCrossRefGoogle Scholar
  69. 69.
    Rogers J, Mastroeni D, Leonard B, Joyce J, Grover A. Neuroinflammation in Alzheimer's disease and Parkinson's disease: are microglia pathogenic in either disorder? Int Rev Neurobiol. 2007;82:235–46.PubMedCrossRefGoogle Scholar
  70. 70.
    Fuster-Matanzo A, Llorens-Martín M, Hernández F, Avila J. Role of neuroinflammation in adult neurogenesis and Alzheimer disease: therapeutic approaches. Mediators Inflamm. 2013;2013:260925.PubMedCentralPubMedCrossRefGoogle Scholar
  71. 71.
    Xia MQ, Hyman BT. Chemokines/chemokine receptors in the central nervous system and Alzheimer's disease. J Neurovirol. 1999;5:32–41.PubMedCrossRefGoogle Scholar
  72. 72.
    Marioni RE, Strachan MW, Reynolds RM, Lowe GD, Mitchell RJ, Fowkes FG, et al. Association between raised inflammatory markers and cognitive decline in elderly people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes. 2010;59:710–3.PubMedCentralPubMedCrossRefGoogle Scholar
  73. 73.
    Luchsinger JA, Reitz C, Honig LS, Tang MX, Shea S, Mayeux R. Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology. 2005;65:545–51.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.The George Institute for Global HealthSydney UniversityCamperdownAustralia

Personalised recommendations